Robert M. Califf, MD, was sworn in as the new commissioner of the U.S. Food and Drug Administration (FDA) on February 17, 2022.
Previously, Dr. Califf served as FDA commissioner from February 2016–February 2017. Prior to rejoining the FDA, Dr. Califf was head of medical strategy and senior advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries, Verily Life Sciences and Google Health. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute.
A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health-care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,300 publications in the peer-reviewed literature.
Dr. Califf will now oversee the federal agency tasked with finalizing and implementing over-the-counter hearing aid regulations.
Recent Posts
Utility of Rotary Chair Testing
In a recent article, Advances in the Clinical Application of Rotational Chair Testing for the Diagnosis and Management of Vestibular Disorders (Ganggang et al., 2026), the…
Congress Averts Government Shutdown Through December
The House voted 370–48 to approve a stopgap funding bill that would keep the federal government operating through December 11, averting a government shutdown before…
Cortical Changes in Total and Partial Vestibular Dysfunction, As Measured by EEG
A recent study by Hadi et al. (2026) analyzed and compared electroencephalogram (EEG) findings in individuals with presumed normal vestibular functions and those with partial…



